WSCC yields 181.82% · ABBV yields 3.06%● Live data
📍 WSCC pulled ahead of the other in Year 1
Combined, WSCC + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of WSCC + ABBV for your $10,000?
Waterside Capital Corporation is no longer investing. It is a venture capital, and private equity firm specializing in investments in mezzanine debt for growth expansion; management buyouts; recapitalizations; leveraged buyouts; acquisitions; and working capital. The firm also provides bridge financing. It seeks to invest in small private and public companies and small middle market companies. The firm does not invest in start-ups, turnaround situations, oil or gas exploration, real estate development, and direct lending businesses. The firm prefers to invest in companies based in the Mid-Atlantic region and also invests in small businesses based in Richmond, Hampton Roads, Virginia, Washington D.C., North Carolina, and Maryland. The firm prefers to provide, with a more than five year term with flexible amortization, between $500,000 and $3 million as subordinate loans and between $1 million and $3 million as senior debt financing. It prefers to invest in companies that have annual revenues greater than $5 million. The firm co-invests in case of large investments and prefers to structure its investments as debt with attached warrants on common stock or as senior debts. The firm prefers equity participation when it provides subordinate loans and a collateral of assets while providing senior debt financing. Westside Capital Corporation was founded in 1993 and is based in Virginia Beach, Virginia.
Full WSCC Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.